Abstract:Objective To evaluate the risk factors of neoatherosclerosis after coronary stent implantation through the study of optical coherence tomography (OCT) observation, and the effect of statin lipid-lowering therapy. Methods The clinical data of 40 patients with coronary heart disease (CHD) after coronary stent implantation (OCT) in Peking University First Hospital from June 2013 to June 2016 were analyzed retrospectively. The patients were divided into the target-achieved group (19 cases, LDL-C<1.8 mmol/L) and the above-target group (21 cases LDL-C ≥ 1.8 mmol/L) according to whether their low density lipoprotein (LDL) levels reached the treatment target. The medical history, biochemical parameters, medication and the qualitative and quantitative analysis of the neoatherosclerosis in the two groups were reviewed and compared. Results There were no statistical differences between the two groups in age, sex, smoking, comorbidities of hypertension, diabetes mellitus, kidney disease, history of myocardial infarction and time of stent implantation. Patients in the above-target group had higher LDL-C levels[(2.42 ± 0.79)mmol/L vs.(1.30 ± 0.35)mmol/L,P<0.001],higher cholesterol levels[(4.38 ±1.01)mmol/L vs.(3.07± 0.87)mmol/L,P<0.001], but lower statin used dosage[(15.26 ±2.30)mg/d vs.(22.38 ± 2.10)mg/d,P=0.032]as compared to patients in the target-achieved group. There was no statistical difference between the other parameter and medication profile. Qualitative analysis showed higher rates of neoatherosclerosis in the above-target group as compared to the target-achieved group(78.9% vs.38.1%,P=0.009),plus higher rates of endothelial heterogeneity(78.9% vs.38.1%,P=0.009),lipid plaque(73.7% vs.38.1%,P=0.024) and calcified plaque(26.3% vs. 4.8%,P=0.049). The rate of neointima restenosis in the above-target group was higher than that of the target-achieved group[(25.12 ±1.10)% vs.(19.70±1.10)%, P=0.001]. Logistic analysis showed that the level of low density lipoprotein(P=0.009),dosage of statin prescribed (P=0.040), male gender (P=0.042) and serum creatinine (P=0.012) were associated with the present of neonatal arteriosclerosis .Multivariate regression analysis showed levels of lipoprotein and low presence of statin dosage were the independent wish factors. Low density lipoprotein levels were positively correlated with neoatherosclerosis formation and the dosage of statin was negatively correlated (P<0.05).Conclusions In-stent restenosis after PCI is closely related to neonatal atherosclerosis. Controlling LDL-C to target levels can significantly reduce the risk of neoatherosclerosis. Intensified statin therapy strategy can prevent neoatherosclerosis in by certain extent.

Increased cholesterol absorption is associated with In-stent-restenosis after stent implantation for stable coronary artery disease

Alterations in Metabolome and Lipidome in Patients with In-Stent Restenosis.

Multiple predictors of in-stent restenosis after stent implantation in symptomatic intracranial atherosclerotic stenosis.

Naturally Occurring Atherosclerosis Progression and In-stent Restenosis: Exploring Histomorphologic Associations Using Optical Coherence Tomography.

To Explore the Relationship between Clinical Serum Markers and Intracoronary in-stent Restenosis

Statin Reduces In-stent Restenosis in Patients with Coronary Heart Disease; Influencing Factors and Implications

Effect of ezetimibe–statin combination therapy vs. statin monotherapy on coronary atheroma phenotype and lumen stenosis in patients with coronary artery disease: a meta-analysis and trial sequential analysis

Abstract P137: Hypercholesterolemia Aggravates In-stent Restenosis In Rabbits By Escalating Vascular Inflammation

Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome

Analysis of related factors of neoatherosclerosis after coronary stent implantation by optical coherence tomography

The profile of cholesterol metabolism does not interfere with the cholesterol-lowering efficacy of phytostanol esters

Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition

Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance

Higher Serum Cystatin C and Matrix Metalloproteinase 9 Levels Effectively Predict In-Stent Restenosis after Stent Implantation for Intracranial and Extracranial Arterial Stenosis

The role of residual inflammatory risk and LDL cholesterol in patients with in-stent restenosis undergoing percutaneous coronary intervention

Evaluation of Antiatherogenic Properties of Ezetimibe Using 3H-Labeled Low-Density-Lipoprotein Cholesterol and 99mTc-cAbVCAM1-5 SPECT in ApoE-/- Mice Fed the Paigen Diet

In-stent restenosis estimation following carotid artery stenting: The robust predictive value of atherogenic index of plasma and other non-traditional lipid profiles

Morphological characteristics of in-stent restenosis with different degrees of area stenosis: an optical coherence tomography study

Increased intestinal ABCA1 expression contributes to the decrease in cholesterol absorption after plant stanol consumption

Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study

Association Between Serum Uric Acid Levels and Neoatherosclerosis